ClinicalTrials.gg
RecruitingNCT07381140RYGB-MICROGUTUpdated Nov 5, 2026

Bariatric Surgery and Gut Microbiota Changes Over Time

An observational study in Obese Patients, Obese Patients With Bariatric Surgery and Gut Microbiota, sponsored by Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 5, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Obesity by Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis — 5 open to participants now, 5 under way, none of them phase 3. Obesity · Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis.

Planned enrollment
7th of 10
100 · median 129
Started
2026
the only one that year
Observational
10 of 15
2 open now
Registered
15th of 15
by date

Among the 15 studies in Obesity by Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis, this one is the 7th largest by planned enrollment of the 10 observational ones that give a count, is the only one that started in 2026, is one of 10 observational ones, and was the 15th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

5 of the 15 studies in Obesity by Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Obesity by Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis, or all of them as a file.
02

Study summary

The goal of this observational study is to learn how bariatric surgery affects gut bacteria and gut-related metabolic products over time in adults with obesity. The study includes adults aged 18 to 65 years who are undergoing Roux-en-Y gastric bypass (RYGB) surgery, as well as adults with obesity treated with diet alone and healthy normal-weight adults.

The main questions it aims to answer are:

How does bariatric surgery change the composition and diversity of gut bacteria over time? How are these changes related to weight loss and improvement of obesity-related health conditions?

Researchers will compare people undergoing bariatric surgery with people with obesity treated with diet alone and with healthy normal-weight individuals to see if surgery leads to specific changes in gut bacteria and stool metabolites that are linked to better clinical outcomes.

Participants will:

Provide stool samples at scheduled time points over 12 months Provide blood samples and undergo routine clinical assessments Take part in follow-up visits to monitor weight, metabolic health, and gastrointestinal symptoms

Read the detailed description

Obesity is a complex and multifactorial condition associated with metabolic, inflammatory, and gastrointestinal alterations. In recent years, the gut microbiota has emerged as a key factor involved in energy balance, metabolic regulation, and systemic inflammation. Alterations in gut microbial composition and function have been consistently observed in individuals with obesity and are thought to contribute to metabolic dysfunction.

Bariatric surgery, particularly Roux-en-Y gastric bypass (RYGB), is one of the most effective treatments for severe obesity and its related comorbidities. Beyond weight loss, this procedure induces profound changes in gastrointestinal anatomy and nutrient flow, which may significantly influence the gut microbiota and the metabolites it produces. However, the timing, persistence, and clinical relevance of these microbial and metabolic changes over the long term are not yet fully understood.

This prospective observational study is designed to evaluate longitudinal changes in gut microbiota composition and fecal metabolome following bariatric surgery and to explore their association with clinical and metabolic outcomes. Participants undergoing bariatric surgery will be followed over a 12-month period and compared with individuals with obesity receiving dietary treatment and with healthy normal-weight individuals. This comparative approach allows the identification of changes specifically related to surgery rather than to weight loss alone or to normal temporal variability.

Gut microbiota will be analyzed using DNA-based sequencing approaches, while fecal metabolites will be assessed to capture functional changes in microbial activity. These biological data will be integrated with clinical and laboratory parameters to explore relationships between gut-related changes and outcomes such as weight loss, metabolic improvement, inflammation, and intestinal barrier function.

By providing a longitudinal and integrated view of gut microbiota and metabolome remodeling after bariatric surgery, this study aims to improve understanding of the biological mechanisms underlying surgical outcomes and to support the identification of potential biomarkers that may help predict individual responses and guide more personalized approaches to obesity management.

03

Conditions studied

  • Obese Patients
  • Obese Patients With Bariatric Surgery
  • Gut Microbiota
  • Healthy Participants

Browse trials for

Keywords

  • gut microbiota
  • stool metabolome
  • obesity
  • bariatric surgery
  • Roux-en-Y gastric bypass
  • Long-read sequencing
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Obese subjects attending the clinical nutrition outpatient clinic of the IRCCS "Saverio de Bellis" - Castellana Grotte (BA).

Eligibility criteria

Inclusion Criteria (RYGB Group):

  • Age between 18 and 65 years.
  • Adults with a (BMI) ≥ 35 kg/m² with related comorbidities, or BMI ≥ 40 kg/m², who are candidates for Roux-en-Y gastric bypass (RYGB) surgery only.

Exclusion Criteria (RYGB Group):

  • Treatment with antibiotics within the last 3 weeks, or probiotics/prebiotics within the last 4-6 weeks, or systemic within the 8 weeks prior to baseline (T0).
  • Participation in dietary regimens or calorie restriction programs in the weeks prior to enrollment.
  • Chronic inflammatory bowel diseases (e.g., Crohn's disease, ulcerative colitis), ongoing enteric infections, or active neoplasms.
  • Previous organ transplant or ongoing systemic therapy.
  • Pregnancy or breastfeeding.
  • Previous major gastrointestinal surgery.
  • Chronic alcohol consumption above moderate levels or substance use disorder.

Inclusion Criteria (Obese Control Group):

  • Age between 18 and 65 years.
  • Adults with BMI ≥ 30 kg/m² who are candidates for structured dietary treatment.

Inclusion Criteria (Healthy Control Group):

  • Age between 18 and 65 years.
  • Normal weight (BMI between 18.5 and 24.9 kg/m²).
  • Normal metabolic function: fasting glucose below threshold, normal /AST, no diagnosis of diabetes or metabolic syndrome.
  • No chronic gastrointestinal diseases or conditions that could alter the gut microbiota.

Exclusion Criteria (Obese Control and Healthy Control Group):

  • Use of antibiotics within the last 3 weeks or probiotics/prebiotics within the last 4-6 weeks.
  • Recent gastrointestinal surgery.
  • Pregnancy or breastfeeding.
  • Extreme diets or recent dietary changes.
  • Recent international travel that could have affected the gut microbiota.
  • Medications known to influence the gut microbiota (e.g., PPIs, metformin, steroids).
  • Active smoking or excessive alcohol consumption.
  • Significant gastrointestinal symptoms (chronic diarrhea or constipation).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • RYGB Group

    Adults aged 18-65 years with severe obesity (BMI ≥ 35 kg/m² with comorbidities or BMI ≥ 40 kg/m²) who are undergoing Roux-en-Y gastric bypass (RYGB) surgery.

  • Obese Control Group

    Adults aged 18-65 years with obesity (BMI ≥ 30 kg/m²) who are receiving structured dietary treatment without surgery.

  • Healthy Control Group

    Adults aged 18-65 years with normal weight (BMI 18.5-24.9 kg/m²) and normal metabolic function. This group helps identify normal variations in gut bacteria and metabolites over time, independent of obesity or surgery.

06

What researchers measure

Primary outcomes

  1. Long-Term Changes in Gut Microbiota After Bariatric Surgery

    Longitudinal changes in the composition and diversity of the gut microbiota (alpha diversity, beta diversity, and relative abundance of key bacterial taxa) in patients undergoing Roux-en-Y gastric bypass (RYGB) surgery, assessed using 16S rRNA gene sequencing (short-read and full-length), compared with the Obese Control and Healthy Control groups.

    Time frame: from enrollment up to 12 months of follow-up

Secondary outcomes

  1. Comparison of Short- and Long-Read 16S Sequencing

    Compare the performance of short-read (V3-V4) and long-read (full-length 16S rRNA) sequencing technologies in terms of taxonomic resolution and biomarker identification.

    Time frame: from enrollment up to 12 months of follow-up

  2. Fecal Metabolome Changes and Predictive Microbe-Metabolite Signatures After Bariatric Surgery

    Assess changes in the fecal metabolome over time after bariatric surgery and Identify microbe-metabolite signatures predictive of clinical response to bariatric surgery.

    Time frame: from enrollment up to 12 months of follow-up

  3. Association Between Gut Microbiota and Clinical Outcomes

    Analyze the association between gut microbiota changes and clinical/metabolic parameters (weight loss, comorbidities, inflammatory and intestinal permeability markers)

    Time frame: from enrollment up to 12 months of follow-up

07

Study locations

1 of 1 sites recruiting
  • Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
    Castellana Grotte, BA 70013, Italy
    Recruiting
08

References and documents

Publications

  • Zhang T, Li H, Ma S, Cao J, Liao H, Huang Q, Chen W. The newest Oxford Nanopore R10.4.1 full-length 16S rRNA sequencing enables the accurate resolution of species-level microbial community profiling. Appl Environ Microbiol. 2023 Oct 31;89(10):e0060523. doi: 10.1128/aem.00605-23. Epub 2023 Oct 6. PubMed 37800969 ↗
  • Oehler JB, Wright H, Stark Z, Mallett AJ, Schmitz U. The application of long-read sequencing in clinical settings. Hum Genomics. 2023 Aug 8;17(1):73. doi: 10.1186/s40246-023-00522-3. PubMed 37553611 ↗
  • Salazar N, Ponce-Alonso M, Garriga M, Sanchez-Carrillo S, Hernandez-Barranco AM, Redruello B, Fernandez M, Botella-Carretero JI, Vega-Pinero B, Galeano J, Zamora J, Ferrer M, de Los Reyes-Gavilan CG, Del Campo R. Fecal Metabolome and Bacterial Composition in Severe Obesity: Impact of Diet and Bariatric Surgery. Gut Microbes. 2022 Jan-Dec;14(1):2106102. doi: 10.1080/19490976.2022.2106102. PubMed 35903014 ↗
  • Palleja A, Kashani A, Allin KH, Nielsen T, Zhang C, Li Y, Brach T, Liang S, Feng Q, Jorgensen NB, Bojsen-Moller KN, Dirksen C, Burgdorf KS, Holst JJ, Madsbad S, Wang J, Pedersen O, Hansen T, Arumugam M; New Collective Author. Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota. Genome Med. 2016 Jun 15;8(1):67. doi: 10.1186/s13073-016-0312-1. PubMed 27306058 ↗
  • De Luca M, Shikora S, Eisenberg D, Angrisani L, Parmar C, Alqahtani A, Aminian A, Aarts E, Brown W, Cohen RV, Di Lorenzo N, Faria SL, Goodpaster KPS, Haddad A, Herrera M, Rosenthal R, Himpens J, Iossa A, Kermansaravi M, Kow L, Kurian M, Chiappetta S, LaMasters T, Mahawar K, Merola G, Nimeri A, O'Kane M, Papasavas P, Piatto G, Ponce J, Prager G, Pratt JSA, Rogers AM, Salminen P, Steele KE, Suter M, Tolone S, Vitiello A, Zappa M, Kothari SN. Scientific Evidence for the Updated Guidelines on Indications for Metabolic and Bariatric Surgery (IFSO/ASMBS). Obes Surg. 2024 Nov;34(11):3963-4096. doi: 10.1007/s11695-024-07370-7. Epub 2024 Sep 25. PubMed 39320627 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Apr 2027, 9 months after the start.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 9 months is below that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

Start moved once since we started tracking on Sep 25, 2026: Apr 2026 → Jul 2026, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2026
First posted
Feb 2, 2026
StartActual
Jul 7, 2026was Apr 2026
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 5, 2026
Sites
Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis is now Recruiting
Nov 5, 2026
Start date
Apr 2026→Jul 7, 2026 (actual)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Not yet recruiting→Recruiting
    Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis is now Recruiting
    Start date Apr 2026→Jul 7, 2026 (now actual)
    + 1 other change: oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07381140
Lead sponsor
Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Responsible party
Domenica Mallardi (Clinical Researcher (Biologist), Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis) — Principal investigator
First posted
Feb 2, 2026
Start date
Jul 7, 2026
Primary completion
Apr 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Domenica Mallardi, Biologist
Contact
domenica.mallardi@irccsdebellis.it
+390804994129
Francesco Russo, MD
Contact
francesco.russo@irccsdebellis.it
+390804994129

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion